Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Registration-based 3D Light Sheet Fluorescence Microscopy and 2D histology image fusion tool for pathological specimen.

Scientific reports·2026
Same author

Right Ventricular to Pulmonary Artery Coupling and Clinical Outcomes after Interatrial Shunting in Heart Failure: Exploratory Analysis of the PRELIEVE study.

ESC heart failure·2026
Same author

Availability of mechanical circulatory support (MCS) and hospital survival in ST-segment elevation myocardial infarction related cardiogenic shock (STEMI-CS).

European heart journal. Acute cardiovascular care·2026
Same author

Left atrial appendage occluder thrombosis caused embolic strokes: a case report.

European heart journal. Case reports·2026
Same author

A Spotlight on Yolk-sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics.

Andrology·2026
Same author

Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial.

ESC heart failure·2026
Same journal

Sparganosis.

The New England journal of medicine·2026
Same journal

Caring for an Aging America - The Looming Crisis of the Long-Term-Care Workforce.

The New England journal of medicine·2026
Same journal

For Those Left Behind.

The New England journal of medicine·2026
Same journal

Colliding Forces - The Aging of the Baby Boom Generation and Contracting Nursing-Home Supply.

The New England journal of medicine·2026
Same journal

Mandated State-Level Surveillance of Assisted Reproductive Technology - An Emerging Threat in the United States.

The New England journal of medicine·2026
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure.

Wolfram-Hubertus Zimmermann1,2,3,4,5,6, Stephan Ensminger7,8, Ingo Kutschka2,9

  • 1Department of Pharmacology and Toxicology, University Medical Center Göttingen, Göttingen, Germany.

The New England Journal of Medicine
|May 27, 2026
PubMed
Summary
This summary is machine-generated.

Biologic ventricular assist tissue (BioVAT) shows promise for cardiac remuscularization, improving heart wall thickness and ejection fraction in heart failure patients. Further research is needed due to adverse events observed in the interim analysis.

More Related Videos

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing
11:09

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Published on: March 19, 2013

Related Experiment Videos

Last Updated: May 29, 2026

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing
11:09

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Published on: March 19, 2013

Area of Science:

  • Regenerative Medicine
  • Cardiovascular Research
  • Biotechnology

Background:

  • Biologic ventricular assist tissue (BioVAT) utilizes engineered heart muscle from allogeneic induced pluripotent stem cells.
  • It is designed for cardiac remuscularization in heart failure patients with reduced ejection fraction.

Purpose of the Study:

  • To evaluate the safety and efficacy of BioVAT transplantation in patients with heart failure.
  • To assess changes in heart wall thickness, left ventricular ejection fraction, and quality of life.

Main Methods:

  • An open-label, phase 1-2 study involving BioVAT transplantation with varying doses (5, 10, or 20 units).
  • Patients received immunosuppression; safety assessed via adverse events.
  • Primary efficacy endpoints included heart wall thickness, ejection fraction, and KCCQ-OSS.

Main Results:

  • The study treated 20 patients; 16 received the maximal safe dose.
  • Significant increases observed in target heart-wall thickness (4.5 mm) and left ventricular ejection fraction (3.9 percentage points) at 3 months.
  • Kansas City Cardiomyopathy Questionnaire-Overall Summary Score (KCCQ-OSS) showed a trend towards improvement (6.7 points); all patients experienced adverse events.

Conclusions:

  • Interim analysis suggests BioVAT cardiac remuscularization increases heart wall thickness, ejection fraction, and KCCQ-OSS.
  • All patients experienced at least one adverse event, necessitating longer-term follow-up.
  • Further clinical investigation is warranted to confirm safety and efficacy.